Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001193125-04-040529
Filing Date
2004-03-12
Accepted
2004-03-12 16:15:31
Documents
9
Period of Report
2003-12-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-K d10k.htm 10-K 603954
3 AMENDMENT AGREEMENT AMONG SALIX PHARMACEUTICALS, INC AND DR. FALK PHARMA GMBH dex1040.htm EX-10.40 13306
4 LICENSE AGREEMENT BETWEEN AAIPHARMA LLC, AAIPHARMA INC AND SALIX PHARMACEUTICALS dex1041.htm EX-10.41 127386
5 MODIFICATION TO COMMERCIAL PROMISSORY NOTE AGREEMENT dex1042.htm EX-10.42 11434
6 CONSENT OF INDEPENDENT AUDITORS dex231.htm EX-23.1 1634
7 CERTIFICATION BY THE CEO PURSUANT TO SECTION 240 dex311.htm EX-31.1 10230
8 CERTIFICATION BY THE CFO PURSUANT TO SECTION 240 dex312.htm EX-31.2 10279
9 CERTIFICATION BY THE CEO PURSUANT TO 18 USC 1350 dex321.htm EX-32.1 3524
10 CERTIFICATION BY THE CEO PURSUANT TO 18 USC 1350 dex322.htm EX-32.2 3699
  Complete submission text file 0001193125-04-040529.txt   788253
Mailing Address 8540 COLONNADE CENTER DR SUITE 501 RALEIGH NC 27615
Business Address 8540 COLONNADE CENTER DR SUITE 501 RALEIGH NC 27615 9198621000
SALIX PHARMACEUTICALS LTD (Filer) CIK: 0001009356 (see all company filings)

EIN.: 943267443 | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 000-23265 | Film No.: 04666318
SIC: 2834 Pharmaceutical Preparations